- Home
- KULR vs ATYR Comparison
KULR vs ATYR Comparison
Compare KULR & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KULR
- ATYR
- Stock Information
- Founded
- KULR 2013
- ATYR 2005
- Country
- KULR United States
- ATYR United States
- Employees
- KULR N/A
- ATYR N/A
- Industry
- KULR Electrical Products
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KULR Technology
- ATYR Health Care
- Exchange
- KULR Nasdaq
- ATYR Nasdaq
- Market Cap
- KULR 275.2M
- ATYR 306.2M
- IPO Year
- KULR N/A
- ATYR 2015
- Fundamental
- Price
- KULR $0.84
- ATYR $5.22
- Analyst Decision
- KULR Strong Buy
- ATYR Strong Buy
- Analyst Count
- KULR 2
- ATYR 6
- Target Price
- KULR $5.00
- ATYR $20.20
- AVG Volume (30 Days)
- KULR 18.1M
- ATYR 2.5M
- Earning Date
- KULR 08-11-2025
- ATYR 08-12-2025
- Dividend Yield
- KULR N/A
- ATYR N/A
- EPS Growth
- KULR N/A
- ATYR N/A
- EPS
- KULR N/A
- ATYR N/A
- Revenue
- KULR $11,436,983.00
- ATYR N/A
- Revenue This Year
- KULR $87.77
- ATYR $960.85
- Revenue Next Year
- KULR $102.93
- ATYR $1,283.47
- P/E Ratio
- KULR N/A
- ATYR N/A
- Revenue Growth
- KULR 16.47
- ATYR N/A
- 52 Week Low
- KULR $0.20
- ATYR $1.42
- 52 Week High
- KULR $5.49
- ATYR $5.98
- Technical
- Relative Strength Index (RSI)
- KULR 33.25
- ATYR 62.87
- Support Level
- KULR $0.73
- ATYR $5.02
- Resistance Level
- KULR $1.32
- ATYR $5.98
- Average True Range (ATR)
- KULR 0.10
- ATYR 0.45
- MACD
- KULR -0.04
- ATYR -0.04
- Stochastic Oscillator
- KULR 17.54
- ATYR 52.94
About KULR KULR Technology Group Inc.
KULR Technology Group Inc develops and commercializes high-performance thermal management technologies for electronics, batteries, and other components. The company is focused on targeting the following applications: electric vehicles and autonomous driving systems; artificial intelligence and Cloud computing; energy storage; and 5G communication technologies.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.